C-Suite Speaks
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Meet DHCOE Acting Chief Brendan O’Leary, FDA’s New Digital Health Guru
In this revealing interview, the new acting director of the US FDA’s Digital Health Center of Excellence talks about his new role at the DHCOE, the big shoes he’ll have to fill now that former center head Bakul Patel is gone, the need for new regulatory frameworks for digital health – and how he helped repair the Hubble Space Telescope.

The Buck Stops Here: BD CEO Tom Polen On How To Make A Medtech Company Succeed
BD CEO Tom Polen is at the bottom of the pyramid – it’s where he wants to be and is best positioned to continue the company’s transition to focusing on high-growth spaces, as set out in the BD2025 strategy.

HealthCap’s Steen On Growing Successful Precision Medicine Businesses
Rising leader Mårten Steen, spoke with In Vivo about translating science into business, building precision medicine firms from the ground up and the importance of high-energy leadership.

The Accidental GastroPsychologist: Building A Business From Behavior Support
Digital health platforms that offer personalized support are gaining traction in the market, both from patients and investors. Trellus Health is connecting IBD patients with resilience methodologies that enable disease management at lower healthcare costs. Its co-founder Laurie Keefer talks to In Vivo about scaling up the business for greater reach within the market.

Building A Company That Challenges The Conventions Of Surgical Robotics
Per Vegard Nerseth is at the helm of CMR Surgical and hopes to transform surgery for good through the widespread introduction of surgical robotics.

Right First Time: SME Innovator Winning The Argument Against Perverse Incentives
In championing Forte Medical’s precision diagnostics technology to improve the quality of urine test samples, 2022 Rising Leader Giovanna Forte has often had to confront market access hurdles. It has not dented her drive to secure widespread adoption of money-saving and outcomes-boosting devices.

All The Way To The Top: Diversity And Inclusion In Pharma Leadership
Policies, programs and strategies promoting diversity and inclusion are almost as ubiquitous in the pharmaceutical industry these days as environmental commitments. That reflects enormous cultural change over the last few generations, hastened in recent history by initiatives such as MeToo or Black Lives Matter.

Africa’s Geographer Of Genes
Nigerian start-up 54gene seeks to be the first private sector enterprise bent on applying Africa’s rich genetic heritage to solve the world’s most intractable diseases – ethically, without boundaries, for all.

From Big Pharma To VC: The Road Travelled By Third Rock’s David Kaufman
VC Playbook: Partner at Third Rock Ventures, David Kaufman, talks to In Vivo about the venture capital firm’s company creation strategy and seeking ‘white space’ in biopharma for innovation.

How Novo Revitalized Its Rare Disease Operations
There is more to the Danish major than diabetes and Ludovic Helfgott gave In Vivo an insight to the firm’s ambitious plans for its renamed rare diseases division.

Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate
Clive Dix was awarded Scrip’s Lifetime Achievement honor jointly with his long-term colleague and friend Dame Kate Bingham in December 2021. With more than 30 years’ experience in pharma and biotech, Dix has seen the industry evolve and take on many challenges. He spoke to In Vivo about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.

CEOs On The COVID Legacy: Medtech Readies For ‘A World That Will Never Be The Same’
The medtech industry’s successful response to the COVID-19 challenge has in some ways made the pre-pandemic years feel like a lifetime ago, in terms of service delivery. That was the consensus at a high-level Medtech Conference panel chaired by LEK consultancy group.

Inside Sanofi’s General Medicines Unit: Embracing A New Commercial Model
Sanofi’s general medicines business will embrace an omnichannel commercial model in 2022 to reduce inefficiencies and stabilize topline growth. Virtual sales reps are on the rise after a tough couple of years managing product promotion and launches online only.

The Missing Link: COVID-19 Antibody Tests Need Buy-In From FDA
Concern looms in many countries as cases of COVID-19 continue to rise due to the delta variant. Vaccines are having a positive effect, but what is the outlook for those still vulnerable to the virus after inoculation? Not everyone will respond to vaccinations in the same way.

Immunomodulating Heat-Killed Bacteria Could Become Staple Of Oncology Treatment
UK-based Immodulon Therapeutics is developing novel immunomodulators in the form of heat-killed bacteria, being trialed in combination with other cancer treatments such as checkpoint inhibitors. The biotech is initially looking at underserved areas, including pancreatic cancer.

Designing A Better Future For Immuno-Oncology: The Power Of ‘Iterative Innovation’
We are at a pivotal point in the reassessment of our approach to innovation, with the value of ‘design thinking’ and an ‘iterative innovation approach’ becoming the most promising solutions to solving the scientific and biological challenges of the future.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.